Clinical trials: Hematology
Myelodysplastic Syndrome
The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
Evaluation of the Efficacy and Safety of Oral Azacitidine plus Best Supportive care versus Placebo and Best Supportive care in subjects with red blood cell (RBC) transfusion-dependent anemia and thrombocytopenia due to…
- Trial name
- NCT01566695
- Testing
- Oral Azacitidine, Best Supportiv Care (BSC)
- Where
- 196 sites in United States, Australia and 21 more
- Volunteers
- 216 people
- Sponsor
- Celgene
Multiple Myeloma
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma
Toward improving the therapeutic index of standard TT3 (S-TT3), the investigators will employ a randomized Phase III trial design to determine whether S-TT3 treatment-related toxicities can be reduced by 50% in TT3-Lite (L-TT3).
- Trial name
- TT4B (NCT00734877)
- Testing
- M-VTD-PACE, TT3-LITE Regimen (L-TT3)
- Where
- United States
- Volunteers
- 382 people
- Sponsor
- University of Arkansas
Chronic Kidney Disease, Chronic Heart Failure
Intravenous Iron in Patients With Severe Chronic Heart Failure and Chronic Kidney Disease
Recently, growing body of evidence support the finding that anemia frequently occurs in patients with chronic heart failure (CHF).
- Conditions
- Chronic Kidney Disease, Chronic Heart Failure, Anemia
- Trial name
- NCT00384657
- Testing
- iron sucrose
- Where
- 2 sites in Romania
- Sponsor
- Anemia Working Group Romania
B-cell Chronic Lymphocytic Leukemia
Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)
This study aims to assess the short term efficacy of a combination immunochemotherapy in patients with relapsed B-cell chronic lymphatic leukemia.
- Trial name
- NCT00147901
- Testing
- FCCam
- Where
- Germany
- Volunteers
- 61 people
- Sponsor
- German CLL Study Group
Recurrent Plasma Cell Myeloma
Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma
This phase I trial studies the side effects and best dose of wild-type reovirus (pelareorep) when given together with dexamethasone, carfilzomib, and nivolumab in treating patients with multiple myeloma that has come back…
- Trial name
- NCT03605719
- Testing
- Carfilzomib, Dexamethasone, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Emory University
Chronic Myeloid Leukemia
TIGIT in Patients With Chronic Myeloid Leukemia
To expresse TIGIT in NK Cells in Patients with Chronic Myeloid Leukemia
- Trial name
- NCT04818619
- Testing
- flow cytometry test
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Assiut University
Lymphoma (Non-Hodgkin's Lymphoma), Hodgkin's Disease or Multiple Myeloma
A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).
This is a research study intended to further investigate the safety and efficacy of plerixafor in patients with NHL, HD, or MM. Patients who have previously failed stem cell mobilisation attempts or who have previously received…
- Conditions
- Lymphoma (Non-Hodgkin's Lymphoma), Hodgkin's Disease or Multiple Myeloma, Front Line Mobilization, Transplantation
- Trial name
- PREDICT (NCT00838357)
- Testing
- Generic = Plerixafor
- Where
- 26 sites in France, Germany and 5 more
- Volunteers
- 118 people
- Sponsor
- Genzyme, a Sanofi Company
Sickle Cell Disease
A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
Study of IMR-687 in adult participants with sickle cell anemia (SCA) (homozygous HbSS or sickle-β0 thalassemia).
- Trial name
- NCT03401112
- Testing
- IMR-687
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 100 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Nursing Education, Simulation Training
Simulation Training for Adolescent Leukemia Care in Nursing Students
This study aims to evaluate the effects of scenario-based simulation training for adolescent leukemia care on nursing students' perceived stress, knowledge level, and learning satisfaction.
- Conditions
- Nursing Education, Simulation Training, Stress, Psychological, Leukemia
- Trial name
- NCT07660770
- Testing
- Scenario-Based Simulation Training
- Where
- Turkey (Türkiye)
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Atılım University
Autoimmune Hemolytic Anemia
Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA)
T follicular helper (TFH) cells represent a T cell subset dedicated to the activation of B cells. They have been involved in the pathogenesis of autoimmune diseases in humans such as lupus and Sjögren disease.
- Trial name
- TFH and AIHA (NCT02828670)
- Testing
- blood sample, spleen sample
- Where
- France
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Hemolytic-Uremic Syndrome
Usefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in Pregnancy
Haemolytic uremic syndrome (HUS) is defined by the presence of the classic triad of non-immune microangiopathic hemolytic anemia (negative direct Coombs), thrombocytopenia and acute renal failure.
- Trial name
- NCT03580941
- Where
- Colombia
- Volunteers
- 75 people
- Sponsor
- Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia
Multiple Myeloma, Smoldering Multiple Myeloma
Imaging in MGUS, SMM and MM
Background: Recent studies have shown that the premalignant conditions monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) have a high risk of progressing to multiple myeloma (MM).
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- NCT01237054
- Testing
- 18-NaF PET, DCE-MRI, 18-FDG PET/CT
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma (MM)
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
The purpose of this study is to evaluate if the addition of SCTC21C to bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma not eligible for transplant will prolong progression-free…
- Trial name
- NCT07297329
- Testing
- SCTC21C, Bortezomib, Lenalidomide
- Where
- China
- Volunteers
- 292 people
- Sponsor
- Sinocelltech Ltd.
Hematologic Neoplasms, Solid Neoplasm
UWCCC Molecular Tumor Board Registry
This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
- Trial name
- NCT03023202
- Testing
- PMMTB (Precision Medicine Molecular Tumor Board)
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- University of Wisconsin, Madison
Chronic Lymphocytic Leukemia
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia
The purpose of this study is to determine whether on course (6 cycles) of consolidation therapy with Revlimid can shrink or slow the growth of Chronic Lymphocytic Leukemia (CLL) in the bone marrow.
- Trial name
- NCT01600053
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Thomas Kipps
Myelofibrosis, Primary Myelofibrosis
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving…
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
- Trial name
- NCT04551053
- Testing
- parsaclisib, ruxolitinib
- Where
- 177 sites in United States, Austria and 17 more
- Volunteers
- 177 people
- Sponsor
- Incyte Corporation
Relapsed or Refractory Multiple Myeloma
Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
This study is a single-center, open and dose-escalation clinical study to evaluate the safety, tolerability, PK/PD characteristics and preliminary efficacy of the investigational drug O\&D-001 injection in the treatment of…
- Trial name
- NCT07369895
- Testing
- Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D
- Where
- China
- Volunteers
- 18 people
- Sponsor
- O&D BioTech Group CO., Limited
Traumatic Brain Injury, Coagulation Disorder
The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
The purpose of this study is to observe the relationship between the level of lipid peroxidation products in serum of patients with traumatic brain injury and secondary coagulation disorders.
- Trial name
- NCT04274777
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Tang-Du Hospital
Multiple Myeloma
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine 1) the safety and tolerability of multiple intravenous doses of anti-CXCR4 (BMS-936564) as monotherapy and as combination, and 2) the maximum tolerated dose (MTD) of BMS-936564 in…
- Trial name
- NCT01359657
- Testing
- Anti-CXCR4 (BMS-936564), Lenalidomide, Dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers
RATIONALE: Gathering information over time about patients' sense of being a burden on their caregiver, and caregivers' sense of burden on themselves, may help doctors learn more about the desire to die in patients with late-stage…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Depression, Leukemia
- Trial name
- NCT00770419
- Testing
- medical chart review, questionnaire administration, psychosocial assessment and care
- Sponsor
- Rutgers, The State University of New Jersey
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.